Humanin peptide is encoded in your own mitochondrial DNA — and may be one of the most underexplored longevity signals in biology. Preclinical research links it to neuroprotection, insulin sensitivity, and extended healthspan. Evaluation is available at TelosRX, subject to medical approval by a licensed provider.
Most peptides arrive from outside — injected BPC-157 for tendons, CJC-1295 to push growth hormone. Humanin flips that picture. Your mitochondria already produce it. The challenge is that output drops measurably with age, and researchers think that decline contributes to neurodegenerative disease, metabolic dysfunction, and accelerated cellular aging.
Discovered in 2001 from surviving neurons in Alzheimer's patients' postmortem brain tissue, humanin appeared to be keeping cells alive when surrounding tissue had already failed. That observation launched two decades of research into what mitochondria are actually signaling — and why their signals slow down as we get older.
What Is the Humanin Peptide?
Humanin is a 24-amino-acid peptide encoded within the 16S rRNA region of mitochondrial DNA. It belongs to a class called mitochondrial-derived peptides (MDPs) — small proteins secreted by mitochondria that circulate as intercellular signals, operating well beyond the cell that produced them.
What makes humanin unusual is its origin. Nearly all known peptides are encoded in cell-nuclear DNA. Humanin comes from a separate genome — the circular DNA your mitochondria inherited from ancient bacteria. That evolutionary history gives it biochemical properties that nuclear-encoded peptides don't share, including a signaling profile shaped by billions of years of stress-response selection.
Humanin circulates in the bloodstream and crosses the blood-brain barrier. Research shows levels decline with age in most species studied. In work at the USC Leonard Davis School of Gerontology, circulating humanin levels in centenarians were significantly higher than in age-matched controls — a consistent finding across multiple cohorts that has prompted serious interest in MDPs as markers and potential modulators of healthy aging.
Humanin is part of a growing MDP family that includes MOTS-c, SHLP2, SHLP3, and SHLP6. Of these, humanin has the longest research history and the broadest studied range of effects across brain, metabolic, and cardiovascular tissue. Each MDP appears to have distinct receptor targets and downstream signaling — supporting the idea that mitochondria run a complex communication network that influences whole-body aging.
How Humanin Works: Mitochondrial Signaling and Cytoprotection
Humanin is classified as a cytoprotective peptide — its core studied function is preventing cells from dying under physiological stress. It does this through multiple receptor-binding interactions at the cell surface.
Humanin binds to a trimeric receptor complex (GP130/WSX-1/CNTFR) and activates downstream survival signaling through three primary pathways: JAK/STAT3, ERK, and PI3K/Akt. These cascades block apoptosis triggered by oxidative stress, inflammatory cytokines, hypoxia, and other stressors that accumulate with aging.
In neural tissue, humanin blocks the pro-apoptotic protein Bax and directly interferes with beta-amyloid aggregation — a central mechanism in Alzheimer's pathology research. In metabolic tissue, it enhances insulin receptor signaling and improves glucose uptake in skeletal muscle models.
There's also a more potent analog called HNG (humanin G) — a single amino acid substitution (S14G) that increases biological potency roughly 1,000-fold in vitro. Most animal model studies showing dramatic effects used HNG rather than natural humanin. When interpreting the research: the magnitude of effects seen with HNG may not translate directly to natural humanin dosing in humans. This distinction is often overlooked when the peptide gets coverage in longevity circles.
Humanin Peptide Research: Longevity, Brain Health, and Metabolism
The evidence base is primarily preclinical — animal models and in vitro cell research, not large-scale human clinical trials. With that context, the consistency across independent research teams is worth understanding.
Longevity research: A 2020 study published in Aging (Yen et al.) found that humanin overexpression in C. elegans extended median lifespan via daf-16/FOXO signaling. Transgenic mice with elevated humanin showed reduced inflammatory markers and improved metabolic parameters consistent with healthspan extension. A 2023 systematic review in Biology (Coradduzza et al.) confirmed humanin levels decline with age across multiple species — but remain stable in naked mole-rats, known for exceptional longevity relative to body size. The naked mole-rat finding is particularly compelling: these animals show minimal senescence and live nearly 10 times longer than similarly sized rodents, and their stable humanin levels may be part of why.
Metabolic effects: Humanin improves glucose uptake and insulin sensitivity in animal models by modulating insulin receptor signaling and mitochondrial energy metabolism. Research in diabetic mouse models shows reduced hepatic glucose output and improved beta-cell function under humanin treatment. These effects appear to work alongside MOTS-c, the other well-studied MDP, which activates AMPK and drives fat oxidation through a separate pathway.
Anti-inflammatory activity: Humanin downregulates pro-inflammatory cytokines including TNF-α and IL-6 in preclinical models. It appears to modulate microglial activation in the central nervous system — the brain's primary inflammatory response mechanism. These anti-inflammatory effects are consistent across multiple independent research teams and are thought to contribute to both neuroprotective and metabolic benefits.
A landmark PMC review positions humanin as a modulator of cellular survival, metabolic health, and inflammation — while noting that large-scale human clinical trials have not yet been completed to validate therapeutic applications.
Humanin and Neuroprotection: What the Research Shows
Neuroprotection is the research area where humanin has received the most consistent attention. The original 2001 discovery came from Alzheimer's tissue, and most early work focused on understanding the survival mechanism.
Humanin exerts neuroprotective effects through at least three documented mechanisms in preclinical models:
- Beta-amyloid interference: Humanin directly binds amyloid-beta peptides and blocks their aggregation into toxic plaques. In neuronal cell models, this reduces amyloid-induced apoptosis substantially.
- Bax inhibition: Bax is a pro-apoptotic protein that, when activated, triggers mitochondrial cell death pathways. Humanin blocks Bax from forming the pores that execute apoptosis.
- STAT3 neuroprotection: Activated STAT3 signaling promotes neuronal survival independently of amyloid pathology, making humanin research relevant across multiple neurodegenerative models.
Research in Parkinson's models shows humanin may protect dopaminergic neurons from experimental toxicity. In hippocampal neuron models, studies report 30–40% reductions in neuronal death when humanin is present — preclinical findings that have not been confirmed by human clinical trials. Humanin is not FDA-approved for any neurological condition.
Whether these mechanisms translate meaningfully to human aging-related cognitive decline remains an open research question. Researchers studying both humanin and other longevity peptides consistently identify this as a priority area for future clinical investigation, given the consistency of the preclinical signal and the limited human intervention data available.
Humanin vs. MOTS-c: Two Mitochondrial-Derived Peptides Compared
Both humanin and MOTS-c are encoded in mitochondrial DNA, both decline with age, and both are studied in longevity research. They work through different mechanisms and are often examined in complementary roles.
| Feature | Humanin | MOTS-c |
|---|---|---|
| Amino acids | 24 residues | 16 residues |
| Molecular weight | ~2,687 Da | ~2,174 Da |
| Primary research area | Neuroprotection, cytoprotection, longevity | Metabolic regulation, fat oxidation, exercise response |
| Key signaling pathway | JAK/STAT3, PI3K/Akt, ERK | AMPK, FOXO, folate cycle |
| Half-life (SC) | ~2–4 hours | ~2–3 hours |
| Brain-relevant research | Strong — Alzheimer's, Parkinson's models | Primarily metabolic / muscle tissue |
| FDA approval status | Not approved for human use | Not approved for human use |
Both are not FDA-approved for clinical use. Access to either requires evaluation by a licensed provider and a provider-issued prescription through a properly structured protocol.
Research on Humanin Dosage and Administration
Humanin has no FDA-approved dosing protocol. All administration data comes from preclinical research and animal models. This is a summary of what the scientific literature reports — not medical advice or a prescription guide.
Preclinical studies have examined dose ranges of 100–300 mcg for neurological endpoints and 100–200 mcg for metabolic endpoints, administered subcutaneously. Animal protocols often used twice or three-times weekly injection schedules with 2–4 week cycles and equal rest periods.
- Sequence: 24 amino acids (MAPRGFSCLLLLTSEIDLPVKRRA)
- Molecular weight: 2,687 Da
- Half-life: ~2–4 hours (subcutaneous)
- Research dose range: 100–300 mcg (no validated human protocol)
- Storage: Refrigerated; reconstituted vials stable 30–60 days
- Key analog: HNG (S14G substitution) — more potent in vitro, same receptor targets
The more potent analog HNG is used in most animal longevity studies. Check whether a study used HNG or unmodified humanin before drawing conclusions about dose-effect magnitude — the gap between the two can be orders of magnitude in preclinical models.
Because humanin is not FDA-approved, any clinical access requires a provider-issued prescription following proper evaluation. TelosRX's asynchronous evaluation process reviews your health history and goals before any peptide protocol is considered — no synchronous in-person visit required.
Humanin Side Effects and Safety Considerations
Humanin is naturally produced by every healthy mitochondria-containing cell in the human body. That endogenous origin gives researchers reason to expect a favorable safety profile compared to fully synthetic compounds, and extensive preclinical studies across multiple species report no significant organ toxicity at research doses.
Reported or theoretically possible adverse effects based on preclinical data:
- Mild injection site reactions (redness, bruising, tenderness) — most commonly noted
- Transient headache or fatigue, particularly at higher doses
- Potential hypoglycemia in insulin-dependent diabetics, given humanin's insulin-sensitizing effects
- Theoretical amplification effects when stacked with other metabolic activators
Groups requiring particular caution: People with active malignancy or recent cancer history. Humanin's anti-apoptotic properties are its core longevity mechanism — preventing stressed cells from dying. In a cancer context, that same mechanism raises a theoretical concern. There is no direct evidence in published research that humanin promotes tumor growth, but researchers consistently flag this as a precautionary consideration requiring careful provider evaluation before use.
Pregnancy, uncontrolled diabetes with hypoglycemia risk, and known hypersensitivity to peptide compounds are also reasons to discuss alternatives with a licensed provider before considering any MDP therapy. Any evaluation at TelosRX includes a structured intake review specifically designed to identify these situations before a protocol is issued.
Frequently Asked Questions
What is humanin peptide and what does it do?
Humanin peptide is a 24-amino-acid compound encoded in mitochondrial DNA. Preclinical research shows it protects cells from apoptosis, supports neuroprotection in neurodegeneration models, improves insulin sensitivity in animal studies, and correlates with extended lifespan in multiple species. It is not FDA-approved for human therapeutic use.
Is humanin FDA-approved?
No. Humanin is classified as a research peptide in the United States — not approved by the FDA for any therapeutic or clinical indication. Any access requires evaluation and a provider-issued prescription through a licensed healthcare provider. It may not be legally sold or marketed for human injection.
How does humanin differ from MOTS-c?
Both are mitochondrial-derived peptides encoded in mtDNA. Humanin primarily operates through JAK/STAT3 and PI3K/Akt pathways to protect cells from death, with emphasis on neuroprotection. MOTS-c activates AMPK, driving metabolic regulation and fat oxidation. Researchers often study them as complementary compounds with distinct but potentially synergistic effects on aging biology.
Does humanin extend lifespan in research models?
In animal models, yes — preclinical studies show humanin overexpression extends median lifespan in C. elegans and improves healthspan markers in transgenic mice. Centenarians show higher circulating humanin than age-matched peers in observational studies. Whether these findings translate to human lifespan extension has not been confirmed by clinical trials.
What is HNG (humanin G) and how does it differ from humanin?
HNG is a modified analog of humanin with a single amino acid substitution at position 14 (serine to glycine) that increases potency roughly 1,000-fold in vitro. Most dramatic animal model results — lifespan extension, metabolic improvements — used HNG rather than unmodified humanin. The clinical relevance of HNG versus natural humanin in human dosing protocols has not been established in clinical trials.
Can humanin improve brain health?
Preclinical research shows humanin interferes with beta-amyloid aggregation, blocks Bax-mediated neuronal death, and may protect dopaminergic neurons from experimental toxicity. Studies report 30–40% reductions in neuronal death in hippocampal models under humanin treatment. These are lab and animal findings only — humanin is not approved for any neurological condition in humans.
What are the potential side effects of humanin?
Preclinical data shows humanin is generally well tolerated at research doses. The most commonly noted effect is mild injection site irritation. Potential concerns include hypoglycemia in diabetic patients due to insulin-sensitizing effects, and a theoretical precaution for those with active malignancy history given humanin's anti-apoptotic mechanism. Human clinical safety data remains limited.
How does humanin relate to mitochondrial aging?
Humanin is produced inside mitochondria as a stress-response signal. As mitochondrial function declines with age, humanin output falls — and the cytoprotective signaling it provides decreases. Researchers propose this age-related drop in MDP production contributes to increased cellular vulnerability in aging tissues, supported by observational data across multiple species and human cohorts studying longevity biology.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.